PDCD1 and cancer: Overall, use of immune checkpoint inhibitor (ICI) therapies targeting the cytotoxic T lymphocyte (CTLA-4) or programmed cell death ligand 1 (PD-L1)/programmed cell death-1 (PD-1) pathway represents a major breakthrough for a number of cancers.